Vaccines (Sep 2024)

Toxicity and Efficacy Evaluation of Soluble Recombinant Ricin Vaccine

  • Hyeongseok Yun,
  • Hae Eun Joe,
  • Dong Hyun Song,
  • Young-Jo Song,
  • Sunghyun Hong,
  • Chang-Hwan Kim,
  • Na Young Kim,
  • Gyeung Haeng Hur,
  • Chi Ho Yu

DOI
https://doi.org/10.3390/vaccines12101116
Journal volume & issue
Vol. 12, no. 10
p. 1116

Abstract

Read online

Background: Ricin, a toxin extracted from the seeds of Ricinus communis, is classified as a ribosome-inactivating protein. The A-subunit of ricin shows RNA N-glycosidase activity that cleaves ribosomal RNA (rRNA) and exhibits toxicity by inhibiting protein synthesis and inducing vascular leak syndrome. Methods: In this study, we created a truncated version of the previously developed R51 ricin vaccine (RTA 1-194 D75C Y80C) through in silico analysis. Results: The resulting R51-3 vaccine showed a more-than-six-fold increase in soluble protein expression when compared to R51, with over 85% solubility. In a pilot toxicity test, no toxicity was observed in hematological and biochemical parameters in BALB/c mice and New Zealand white rabbits following five repeated administrations of R51-3. Furthermore, R51-3 successfully protected mice and rabbits from a 20 × LD50 ricin challenge after three intramuscular injections spaced 2 weeks apart. Similarly, monkeys that received three injections of R51-3 survived a 60 µg/kg ricin challenge. Conclusions: These findings support R51-3 as a promising candidate antigen for ricin vaccine development.

Keywords